A Phase 2a, Placebo-Controlled, Randomized, Single-Blind Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease.

Trial Profile

A Phase 2a, Placebo-Controlled, Randomized, Single-Blind Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2015

At a glance

  • Drugs GCS 100 (Primary)
  • Indications Renal failure
  • Focus Therapeutic Use
  • Sponsors La Jolla Pharmaceutical Company
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Nov 2014 Results were presented at the American Society of Nephrology's (ASN) Kidney Week Annual Meeting according to a La Jolla Pharmaceutical Company media release reporting the results.
    • 12 Nov 2014 Primary endpoint (Change in eGFR from baseline relative to placebo after administration of GCS-100 for 8 weeks in patients with CKD) has been met for 1.5 mg/m2 dose but not for 30 mg/m2 dose according to a La Jolla media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top